021-51111890
购物车（）
sales@molnova.cn
Atuveciclib Racemate
CAS No. 1414943-88-6
Atuveciclib Racemate ( BAY-1143572 Racemate )
产品货号. M21757 CAS No. 1414943-88-6
Atuveciclib Racemate (BAY-1143572 Racemate) 是 Atuveciclib 的外消旋混合物。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥4590 | 有现货 |
|
| 10MG | ￥7110 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Atuveciclib Racemate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Atuveciclib Racemate (BAY-1143572 Racemate) 是 Atuveciclib 的外消旋混合物。
-
产品描述Atuveciclib (BAY-1143572) inhibits the proliferation of 7 MLL-rearrangements positive and negative AML cell lines with a median IC50 of 385 nM (range 230-1100 nM) and induces apoptosis. Atuveciclib (BAY-1143572) has potent and highly selective PTEFb-kinase inhibitory activity in the low nanomolar range against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs. Atuveciclib (BAY-1143572) shows a favorable selectivity against a panel of non-CDK kinases. It shows broad antiproliferative activity against a panel of tumor cell lines with sub-micromolar IC50 values. The concentration-dependent inhibition of the phosphorylation of the RNA polymerase II and downstream reduction of MYC mRNA and protein levels is observed.
-
体外实验——
-
体内实验——
-
同义词BAY-1143572 Racemate
-
通路Angiogenesis
-
靶点CDK
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number1414943-88-6
-
分子量387.43
-
分子式C??H??FN?O?S
-
纯度>98% (HPLC)
-
溶解度DMSO : 100 mg/mL (258.11 mM; Need ultrasonic)
-
SMILESN=S(CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl)
产品手册
